Assessing permeability biomarkers of dual responders in allergic asthmatics

N. van der Burg (Lund, Sweden), H. Stenberg (Lund, Sweden), Z. Diamant (Groningen, Netherlands), L. Bjermer (Lund, Sweden), E. Tufvesson (Lund, Sweden)

Source: Virtual Congress 2020 – Phenotypes of asthma and COPD
Session: Phenotypes of asthma and COPD
Session type: E-poster session
Number: 1112
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. van der Burg (Lund, Sweden), H. Stenberg (Lund, Sweden), Z. Diamant (Groningen, Netherlands), L. Bjermer (Lund, Sweden), E. Tufvesson (Lund, Sweden). Assessing permeability biomarkers of dual responders in allergic asthmatics. 1112

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The diagnostic value of biomarkers in allergic and non-allergic asthma phenotype
Source: International Congress 2018 – Asthma, rhinitis and COPD: cells, mediators, biomarkers and genetics
Year: 2018


Exploring inflammation-related plasma biomarkers in young adults with allergic- or non-allergic asthma
Source: Virtual Congress 2021 – Lung disease burden and management
Year: 2021


Changes in lung functions and inflammatory markers in induced sputum of patients with bronchial asthma and allergic rhinitis in relation to exposure to pollen allergens
Source: Eur Respir J 2005; 26: Suppl. 49, 734s
Year: 2005

Assessing bronchodilator response in patients with asthma and COPD using 19F-MRI
Source: Virtual Congress 2020 – New imaging techniques applied to old problems
Year: 2020


Is DawNO a new measurement to characterise allergic and non-allergic asthma?
Source: Annual Congress 2009 - One size (does not) fit all: phenotyping and controlling asthma
Year: 2009


Role of neutrophils in maintenance of severity of non-allergic asthma
Source: Eur Respir J 2007; 30: Suppl. 51, 585s
Year: 2007

Evaluation of the effect of inhaled ciclesonide on inflammatory and allergic markers and pulmonary function in bronchial asthma
Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy
Year: 2008


Markers of inflammation and airway responses to allergen in asthmatic patients
Source: Annual Congress 2008 - Asthma: growing understanding of influential factors
Year: 2008

Variants of allergic response in children with bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 162s
Year: 2004

Identification of disease-specific molecular breath profiles in patients with allergic asthma
Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma
Year: 2020


Effect of an inhaled alpha4-antagonist on the allergen-induced late asthmatic response in patients with mild asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 135s
Year: 2005

Reactance for bronchial reactivity is a useful clinical marker in differentiating cough-variant asthma from classic asthma
Source: Annual Congress 2008 - Clinical aspects of asthma in school-aged children
Year: 2008


Baseline airway inflammation may be a determinant of ozone response in asthmatic patients
Source: Annual Congress 2012 - Bronchial challenge as a biomarker of respiratory disease
Year: 2012

Relationship between bronchial hyperresponsiveness and response to β2-agonists in steroid-naïve patients with mild asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 503s
Year: 2002

eNose breathprints as surrogate biomarkers for classifying asthma patients by atopy
Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases
Year: 2019




Humoral markers of inflammation in induced sputum of patients with bronchial asthma and allergic rhinitis in relation to exposure to pollen allergens
Source: Eur Respir J 2004; 24: Suppl. 48, 595s
Year: 2004

Utility of Interleukin-5 in phenotyping allergic versus non allergic asthma
Source: Virtual Congress 2021 – Advances in asthma treatment: monoclonal antibodies
Year: 2021


Relationship between omalizumab efficacy and baseline allergen profile impacts patient-reported outcomes in allergic asthma
Source: International Congress 2018 – Tests and trends in asthma
Year: 2018

Omalizumab therapy reduces asthma exacerbations in children with severe allergic (IgE-mediated) asthma irrespective of lung function at baseline
Source: Annual Congress 2009 - Difficult asthma in children: diagnostic and therapeutic challenges
Year: 2009

Evaluation of the bronchial inflammation in allergic rhinitic patients following the new ARIA guidelines
Source: Eur Respir J 2003; 22: Suppl. 45, 108s
Year: 2003